A Single-arm, Multicenter, Phase III Study to Assess Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients of 2 to <18 Years of Age With Primary Immunoglobulin A Nephropathy (IgAN) (CEXV811B12301)

未提供0 个研究点目标入组 2 人开始时间: 待定

适应症

试验速览

阶段: 不适用
状态: 尚未招募
入组人数: 2

研究概览研究设计入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional
分配方式: Single Arm Study

入排标准

年龄范围: 2age old over 至 18age old not（—）
性别: All

入选标准

•Signed informed consent by parent(s)/legal guardian(s) for the pediatric patient must be obtained before any study-specific assessment is performed. A consent or assent may also be required for some participants depending upon their age and local requirement.
•Male and female participants 2 to < 18 years of age as of Day
•eGFR >= 30 mL/min/1.73m2 where eGFR is calculated using the modified Schwartz formula at Screening and confirmed during the Run-in Period.
•Kidney biopsy-proven primary IgAN, with biopsy performed within 3 years of Screening with < 50% tubulointerstitial fibrosis and < 25% crescents. In case a kidney biopsy within 3 years from Screening is not available, a kidney biopsy may be performed if it is part of the planned diagnostic approach and clinical management of the participant.
•Proteinuria due to primary diagnosis of IgAN as assessed by UPCR >= 1 g/g (113 mg/mmoL) sampled from FMV at Screening on Day -90 and Day -60 as well as during the Run-in Period despite treatment with maximum tolerated dose of ACE inhibitor/ARB for at least 120 days prior to Day
•Note: UPCR will be assessed based on one FMV sample at Day -90 and based on the geometric mean of 2 FMV samples for the Day -60 visit and during the Run-in Period.
•All participants must have been on supportive care including stable dose regimen of ACE inhibitor or ARB at either the locally approved maximal daily dose per body weight, or the maximally tolerated dose (per Investigator's judgment for pediatric use), for at least 120 days before first study drug administration. In addition, if participants are taking diuretics, other antihypertensive medication, or other background medication for IgAN (such as SGLT2 inhibitors), the doses should also be stabilized for at least 120 days prior to the first dosing of study treatment. Note: Participants with allergies or intolerance to ACE inhibitors and ARBs are eligible for the study. Participants with allergies or intolerance to RAS inhibitors are eligible but will not exceed ~5% of the total population treated (maximum of 2 participants).
•The minimum body weight of enrolled pediatric participants is 10 kg at Screening and confirmed on Day
•Parent(s)/guardian(s) are to be able to communicate well with the investigator and to understand and comply with the study's requirements for their child.

排除标准

•Participation in any other investigational drug trial or use of other investigational drugs at the time of enrollment, or within 5 elimination half-lives of enrollment, or within 30 days of enrollment, whichever is longer; or longer if required by local regulations.
•History of hypersensitivity to any of the study drugs or its excipients or to drugs of similar chemical classes.
•Any secondary IgAN as defined by the investigator.
•A clinical diagnosis of IgA vasculitis (IgAV or Henoch-Schoenlein purpura) based on typical palpable purpura with or without arthralgia and abdominal pain.
•Evidence of significant urinary obstruction or difficulty in voiding, any urinary tract disorder causing significant urinary obstruction or difficulty in voiding at Screening and confirmed at Baseline/Day
•Concurrent diagnosis of CKD other than IgAN at Screening and before first study drug administration.
•Current acute kidney injury (AKI) defined by Acute Kidney Injury Network (AKIN) criteria within 4 weeks of Screening.
•Presence of rapidly progressive glomerulonephritis (RPGN) as defined by 50% decline in eGFR within 3 months prior to Screening or during Screening and Run-in periods.
•Presence of nephrotic syndrome at Screening based on the investigator's judgement.
•BNP value of >200 pg/mL at Screening.
•Hemoglobin below 9 g/dL at Screening or prior history of blood transfusion for anemia within 3 months of Screening.
•Platelet count <80,000/microL at Screening.
•On Day 1 participants' body weight falls below the lower limit of the cohort in which the participant was initially screened and lower body weight cohort is not open for enrollment.
•Known history of congenital heart disease, heart failure or clinically significant fluid retention such as pulmonary edema, uncontrolled peripheral edema, pleural effusion, or ascites before treatment.
•Current use of any homeopathic and/or herbal medications for the treatment of IgAN disease.
•History of an alcohol or illicit drug-related disorder within the past 3 years at Screening.
•Confirmed blood pressure >150 mmHg systolic or >95 mmHg diastolic for 12 to <18 years of age; >140 mmHg systolic or >90 mmHg diastolic for 6 to <12 years of age; >120 mmHg systolic or >80 mmHg diastolic for 2 to <6 years of age; based on the mean of 3 measurements obtained at Screening; or clinically significant hypotension at screening.
•Participants previously treated with immunosuppressive or other immunomodulatory agents. Participants treated with endothelin (receptor) antagonists (including sparsentan) within 120 days prior to first study drug administration.
•History of organ transplantation (subjects with history of corneal transplant are not excluded) before treatment.
•Major concurrent comorbidities before treatment.
•Any medical condition deemed likely to interfere with the subject's participation in the study before treatment.
•Active systemic bacterial infection within 14 days prior to study drug administration.
•Presence of fever >= 38 celsius degree (100.4 fahrenheit degree) within 7 days prior to study drug administration.
•Human immunodeficiency virus (HIV) infection.
•Liver disease, such as active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection defined as Hepatitis B surface antigen (HBsAg) positive or Hepatitis C virus ribonucleic acid (HCV-RNA) positive at Screening, or liver injury as indicated by abnormal liver function tests at Screening and Baseline as defined below:
•Any single parameter of ALT, AST, GGT, alkaline phosphatase must not exceed 3X upper limit of normal (ULN)
•Serum bilirubin must not exceed 2X ULN
•History of malignancy of any organ system (except for predefined exceptions).
•Pregnant or nursing (lactating) female participants (of childbearing potential).
•Subjects taking prohibited therapies before treatment.
•Women of childbearing potential, defined as all women physiologically capable of becoming pregnant from menarche until becoming post-menopausal, unless they are using highly effective methods of contraception (failure rate < 1% per year) while taking study treatment and for 1 month after stopping study treatment.

研究者

发起方

未提供

相似试验

尚未招募

不适用

A Phase 3 Study of Pegcetacoplan in Japanese Participants with Geographic Atrophy Secondary to Age-related Macular DegenerationGeographic Atrophy Secondary to Age-related Macular Degeneration

jRCT207126000920

招募中

不适用

A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast CancerPIK3CA-mutated HER2-positive locally advanced or metastatic breast cancer

jRCT2031250577230

招募中

不适用

A Phase 1 Study of MK-4884 for Advanced/Metastatic Solid Tumorsadvanced/metastatic solid tumorsadvanced/metastatic solid tumors (CRC, RCC, NSCLC, BTC)

jRCT20312601236

招募中

不适用

Phase III study of KD2-396Prevention of pertussis, diphtheria, tetanus, poliomyelitis(polio), Hib infection, and hepatitis B

jRCT2031250804540

尚未招募

不适用

A study to find out if enfortumab vedotin given with pembrolizumab helps people with muscle-invasive bladder cancer keep their bladderMuscle-invasive Bladder Cancer

jRCT2031260003240